Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

11. april 2018 oppdatert av: Minh Tam Truong, Boston Medical Center

Feasibility and Outcome of Cyberknife® Precision Hypofractionated Radiosurgery for the Curative Management of Non-Small Cell Lung Cancer

RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue.

PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiosurgery in treating patients with stage I or stage II non-small cell lung cancer.

Studieoversikt

Detaljert beskrivelse

OBJECTIVES:

  • To establish the maximum tolerated dose of CyberKnife® hypofractionated stereotactic radiosurgery in patients with medically inoperable, stage I or II non-small cell lung cancer.
  • To establish the relationship between positron emission tomography (PET) response and local control and survival using fludeoxyglucose F 18 PET/CT imaging before treatment and at 1, 3, 6, and 12 months after treatment.

OUTLINE: Patients undergo placement of 3 gold fiducial markers by CT-guidance or bronchoscopy. Patients then undergo CyberKnife® hypofractionated stereotactic radiosurgery over 45-120 minutes twice weekly for 2 weeks.

Patients undergo fludeoxyglucose F 18 PET/CT scan at baseline and at 1, 3, 6, and 12 months after completion of treatment.

After completion of study treatment, patients are followed periodically for up to 4 years.

Studietype

Intervensjonell

Registrering (Faktiske)

9

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02118
        • Boston University Cancer Research Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

DISEASE CHARACTERISTICS:

  • Histologically confirmed non-small cell lung cancer

    • Stage I or II disease (T1-3, N0, M0)

      • T2 or T3 tumor ≤ 5 cm
      • No T3 tumors involving the central chest or mediastinum (only chest wall involvement allowed)
  • Tumor deemed technically resectable, in the opinion of an experienced thoracic surgeon, AND patient deemed "medically inoperable"

    • Patients with fluorodeoxyglucose (FDG)-avidity in mediastinal lymph nodes are eligible provided they are able to undergo mediastinoscopy to confirm N0 status

PATIENT CHARACTERISTICS:

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Not pregnant or nursing
  • Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment

Exclusion Criteria:

  • No history of contrast allergy
  • No psychological issues that would preclude the completion of study treatment

PRIOR CONCURRENT THERAPY:

  • No prior radiotherapy or chemotherapy
  • No suspected nodal metastasis that cannot be falsified by mediastinoscopy (i.e., hilar or mediastinal nodes that are either fludeoxyglucose F 18 [FDG]-avid or measure > 1 cm in short axis diameter on CT scan)
  • No tumor within or touching the proximal bronchial tree, defined as a volume of 2 cm in all directions around the proximal bronchial tree (carina, right and left main stem bronchi, right and left upper lobe bronchi, bronchus intermedius, right middle lobe bronchus, lingular bronchus, right and left lower lobe bronchi)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: 56 Gray (LESS than 3 centimeter cohort)

Intervention:

Procedure/Surgery: computed tomography Standard CT scans

Intervention:

Radiation: fludeoxyglucose F 18 standard doses with CT scans

Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray

Radiation: stereotactic radiosurgery CyberKnife radiosurgery

Standard CT scans
standard doses with CT scans
4 doses over 2 weeks
CyberKnife radiosurgery
Eksperimentell: 62 Gray (LESS than 3 centimeter cohort)

Intervention:

Procedure/Surgery: computed tomography Standard CT scans

Intervention:

Radiation: fludeoxyglucose F 18 standard doses with CT scans

Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray

Radiation: stereotactic radiosurgery CyberKnife radiosurgery

Standard CT scans
standard doses with CT scans
4 doses over 2 weeks
CyberKnife radiosurgery
Eksperimentell: 68 Gray (LESS than 3 centimeter cohort)

Intervention:

Procedure/Surgery: computed tomography Standard CT scans

Intervention:

Radiation: fludeoxyglucose F 18 standard doses with CT scans

Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray

Radiation: stereotactic radiosurgery CyberKnife radiosurgery

Standard CT scans
standard doses with CT scans
4 doses over 2 weeks
CyberKnife radiosurgery
Eksperimentell: 56 Gray (MORE than 3 centimeter cohort)

Intervention:

Procedure/Surgery: computed tomography Standard CT scans

Intervention:

Radiation: fludeoxyglucose F 18 standard doses with CT scans

Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray

Radiation: stereotactic radiosurgery CyberKnife radiosurgery

Standard CT scans
standard doses with CT scans
4 doses over 2 weeks
CyberKnife radiosurgery
Eksperimentell: 62 Gray (MORE than 3 centimeter cohort)

Intervention:

Procedure/Surgery: computed tomography Standard CT scans

Intervention:

Radiation: fludeoxyglucose F 18 standard doses with CT scans

Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray

Radiation: stereotactic radiosurgery CyberKnife radiosurgery

Standard CT scans
standard doses with CT scans
4 doses over 2 weeks
CyberKnife radiosurgery
Eksperimentell: 68 Gray (MORE than 3 centimeter cohort)

Intervention:

Procedure/Surgery: computed tomography Standard CT scans

Intervention:

Radiation: fludeoxyglucose F 18 standard doses with CT scans

Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray

Radiation: stereotactic radiosurgery CyberKnife radiosurgery

Standard CT scans
standard doses with CT scans
4 doses over 2 weeks
CyberKnife radiosurgery

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Participants Who Did Not Experience a Dose Limiting Toxicity in the Less Than 3 Centimeter Cohort
Tidsramme: 6 weeks
Number of Participants Who Did Not Experience a Dose Limiting Toxicity in the less than 3 centimeter cohort
6 weeks
Maximum Tolerated Dose in the Less Than 3 Centimeter Cohort
Tidsramme: 6 weeks
The highest tolerable dose between 56 gray, 62 gray and 68 gray has not been established as the protocol was terminated early.
6 weeks
Participants Who Did Not Experience a Dose Limiting Toxicity in the More Than 3 Centimeter Cohort
Tidsramme: 6 weeks
The number of participants that did not experience a dose-limiting toxicity in the greater than 3 centimeter cohort
6 weeks
Maximum Tolerated Dose - More Than 3 Centimeter Cohort.
Tidsramme: 6 weeks
The highest tolerable dose between 56 gray, 62 gray and 68 gray has not been established as the protocol was terminated early.
6 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Relationship Between Positron Emission Tomography (PET) Response and Local Control and Survival
Tidsramme: before treatment and at 1, 3, 6, and 12 months after treatment
Relationship between positron emission tomography (PET) response and local control and survival as measured by fludeoxyglucose F 18 PET/CT imaging
before treatment and at 1, 3, 6, and 12 months after treatment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Minh Tam Truong, MD, Boston Medical Center

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. januar 2009

Primær fullføring (Faktiske)

1. juni 2013

Studiet fullført (Faktiske)

1. august 2016

Datoer for studieregistrering

Først innsendt

26. februar 2009

Først innsendt som oppfylte QC-kriteriene

26. februar 2009

Først lagt ut (Anslag)

27. februar 2009

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

11. mai 2018

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. april 2018

Sist bekreftet

1. april 2018

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere